Novolin r and Exjade drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Novolin r (insulin recombinant purified human) and Exjade (deferasirox). Common drug interactions include blood creatinine increased among females and rash maculo-papular among males.
The phase IV clinical study analyzes what interactions people have when they take Novolin r and Exjade. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.
What is Novolin r?
Novolin r has active ingredients of insulin recombinant purified human. It is often used in type 1 diabetes. eHealthMe is studying from 4,568 Novolin r users. Check the latest studies of Novolin r.
What is Exjade?
Exjade has active ingredients of deferasirox. It is often used in iron overload. eHealthMe is studying from 29,456 Exjade users. Check the latest studies of Exjade.
23 people who take Novolin r and Exjade together, and have interactions are studied.

What are the common drug interactions of Novolin R and Exjade, by gender? *:
female:
- Blood creatinine increased
- Renal impairment (severely reduced kidney function)
- Dehydration (dryness resulting from the removal of water)
- Back pain
- Blood alkaline phosphatase increased
- Herpes zoster
- Pneumonia
- Pubis fracture
- General physical health deterioration (weak health status)
- Neutropenia (an abnormally low number of neutrophils)
male:
- Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
- Malaise (a feeling of general discomfort or uneasiness)
- Platelet count decreased
- Pyrexia (fever)
- Vomiting
- White blood cell count decreased
- Arthralgia (joint pain)
- Blood chloride increased
- Blood creatinine increased
- Cardiac failure
What are the common drug interactions of Novolin R and Exjade, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
- Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
- Malaise (a feeling of general discomfort or uneasiness)
- Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
- Haemoglobin decreased
- Platelet count decreased
- Pyrexia (fever)
- Vomiting
- White blood cell count decreased
20-29:
n/a
30-39:
- Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)
- Blood creatinine increased
- Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
- Bronchopulmonary aspergillosis (lung disorder caused by aspergillus fungi)
- Disease progression
- Febrile neutropenia (fever with reduced white blood cells)
- Hyperamylasaemia (acute pancreatitis in which serum amylase is usually elevated more than 4-fold)
- Nausea (feeling of having an urge to vomit)
- Renal impairment (severely reduced kidney function)
- Stomatitis (inflammation of mucous membrane of mouth)
40-49:
n/a
50-59:
- Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
- Bacterial infection
- Gastric ulcer haemorrhage (bleeding ulcer of stomach)
- Pulmonary embolism (blockage of the main artery of the lung)
- Respiratory failure (inadequate gas exchange by the respiratory system)
- Secondary hypertension (elevated blood pressure that results from an underlying, identifiable, often correctable cause)
60+:
- Blood creatinine increased
- Dehydration (dryness resulting from the removal of water)
- Sepsis (a severe blood infection that can lead to organ failure and death)
- Thrombocytopenia (decrease of platelets in blood)
- Urinary tract infection
- Blood urea increased
- Renal failure (kidney dysfunction)
- Cardiac failure congestive
- Death
- Arthralgia (joint pain)
What are the existing conditions these people have? *
- Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 12 people, 52.17%
- Oropharyngeal Pain: 3 people, 13.04%
- Neuropathy Peripheral (surface nerve damage): 3 people, 13.04%
- Nausea (feeling of having an urge to vomit): 3 people, 13.04%
- Myeloid Leukaemia (a type of cancer in which the bone marrow makes abnormal myeloblasts): 3 people, 13.04%
- Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 3 people, 13.04%
- High Blood Pressure: 2 people, 8.70%
- Hereditary Haemochromatosis (hereditary condition -excessive amounts of iron accumulate in the body tissues): 2 people, 8.70%
- Aplastic Anemia: 2 people, 8.70%
* Approximation only. Some reports may have incomplete information.
Do you take Novolin r and Exjade?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Novolin r and Exjade:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Novolin r:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Exjade:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Novolin r and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Exjade and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on insulin recombinant purified human and deferasirox (the active ingredients of Novolin r and Exjade, respectively), and Novolin r and Exjade (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Guanfacine Hydrochloride vs. Modafinil, side effect and effectiveness comparison - 6 seconds ago
- Could Curosurf cause Necrotising Enterocolitis Neonatal? - 6 seconds ago
- Transient Ischaemic Attack and Speech Disorder - 15 seconds ago
- Could Amlodipine cause Brain Abscess? - 23 seconds ago
- Zyprexa Zydis vs. Zanaflex, side effect and effectiveness comparison - 24 seconds ago
- Drug interactions of Zonegran and Simvastatin - 25 seconds ago
- Abacavir Sulfate; Lamivudine vs. Isentress, side effect and effectiveness comparison - 31 seconds ago
- Drug interactions of Elavil and Baycol - 35 seconds ago
- Could Prograf cause Hyperparathyroidism? - 46 seconds ago
- Could Methotrexate cause Mean Cell Volume Abnormal? - 48 seconds ago